AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35927645 — intervention group
Group type: EXPERIMENTAL
Intervention: TC-PEEK cages
Number of subjects: 104
Study 35927645 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant-to-bone surface ratio
Number of subjects: 104
Study 35524188 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training (A)
Number of subjects: 285
Study 35524188 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training (B)
Number of subjects: 285
Study 35524188 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined cognitive and physical training (C)
Number of subjects: 285
Study 35524188 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed ABC, A + B, C + A, B + C (various combinations of cognitive and physical training)
Number of subjects: 285
Study 35524188 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 285
Study 33603039 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Intermittent Exercise (HIIE)
Number of subjects: 14
Study 33603039 — intervention group
Group type: COMPARATOR
Intervention: Control (Menstrual Phase Effects)
Number of subjects: 14
Study 35398573 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-budget exoscope
Number of subjects: 16
Study 35398573 — intervention group
Group type: COMPARATOR
Intervention: Conventional binocular microscope
Number of subjects: 16
Study 33372062 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 76
Study 33372062 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 76
Study 33372062 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep-deprived wakefulness
Number of subjects: 76
Study 33372062 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-rapid eye movement sleep
Number of subjects: 76
Study 33532608 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity training (HIT) for 4 weeks, exercising 3 times a week on a cycle ergometer, achieving ≥ 90% max heart rate during each exercise session.
Number of subjects: 0
Study 33532608 — intervention group
Group type: COMPARATOR
Intervention: No exercise (control group) for 4 weeks, receiving additional advice on hypoglycaemia avoidance.
Number of subjects: 0
Study 32553191 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% olanexidine
Number of subjects: 587
Study 32553191 — intervention group
Group type: COMPARATOR
Intervention: 10% povidone-iodine
Number of subjects: 587
Study 36206636 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (15,000 IU)
Number of subjects: 110
Study 36206636 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 33787519 — intervention group
Group type: EXPERIMENTAL
Intervention: Bern classification system
Number of subjects: 42
Study 33787519 — intervention group
Group type: COMPARATOR
Intervention: Beck classification
Number of subjects: 42
Study 33787519 — intervention group
Group type: COMPARATOR
Intervention: Konan classification
Number of subjects: 42
Study 33787519 — intervention group
Group type: COMPARATOR
Intervention: Outerbridge classification
Number of subjects: 42
Study 33787519 — intervention group
Group type: COMPARATOR
Intervention: Peters classification
Number of subjects: 42
Study 33787519 — intervention group
Group type: COMPARATOR
Intervention: Lage classification
Number of subjects: 42
Study 33787519 — intervention group
Group type: COMPARATOR
Intervention: Beck classification for labral lesions
Number of subjects: 42
Study 32347147 — intervention group
Group type: EXPERIMENTAL
Intervention: ECPR
Number of subjects: 129736
Study 35264713 — intervention group
Group type: COMPARATOR
Intervention: Routine therapeutic program
Number of subjects: 60
Study 35264713 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined respiratory exercises with routine therapeutic program
Number of subjects: 60
Study 35264713 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 33218309 — intervention group
Group type: EXPERIMENTAL
Intervention: Photo‐Integrated Conversation Moderated by Robots (PICMOR) intervention
Number of subjects: 61
Study 32713109 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg of azithromycin 3 times weekly for 4 months
Number of subjects: 48
Study 32713109 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 32005336 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdiagnostic cognitive behavior therapy (CBT)
Number of subjects: 223
Study 32005336 — intervention group
Group type: EXPERIMENTAL
Intervention: Disorder-specific cognitive behavior therapy (CBT)
Number of subjects: 223
Study 32005336 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 223
Study 32005336 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT (both transdiagnostic and disorder-specific)
Number of subjects: 223
Study 32005336 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment (CBT)
Number of subjects: 223
Study 36471362 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of three-dimensional visualization technology with the PBL teaching mode
Number of subjects: 106
Study 36471362 — intervention group
Group type: COMPARATOR
Intervention: Traditional teaching method
Number of subjects: 106
Study 34340917 — intervention group
Group type: EXPERIMENTAL
Intervention: Volumetric contouring protocol
Number of subjects: 327
Study 34340917 — intervention group
Group type: COMPARATOR
Intervention: Anatomical contouring protocol
Number of subjects: 327
Study 33164281 — intervention group
Group type: EXPERIMENTAL
Intervention: Running exercises at 30% HRR
Number of subjects: 0
Study 33164281 — intervention group
Group type: EXPERIMENTAL
Intervention: Running exercises at 60% HRR
Number of subjects: 0
Study 33164281 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 0
Study 32325005 — intervention group
Group type: EXPERIMENTAL
Intervention: Home monitoring program (including home spirometry, reporting of symptoms and side effects, patient-reported outcomes, information, a medication coach, and eConsultations)
Number of subjects: 90
Study 32325005 — intervention group
Group type: EXPERIMENTAL
Intervention: Home monitoring program
Number of subjects: 90
Study 32325005 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 90
Study 35830893 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus polychemotherapy
Number of subjects: 0
Study 35830893 — intervention group
Group type: COMPARATOR
Intervention: Polychemotherapy alone (control)
Number of subjects: 0
Study 34597872 — intervention group
Group type: EXPERIMENTAL
Intervention: Raising doubt about desirable anticipated consequences of suicide in a virtual reality (VR) setting.
Number of subjects: 639
Study 34597872 — intervention group
Group type: EXPERIMENTAL
Intervention: Raising doubt about the anticipated consequences of attempting suicide by firearm.
Number of subjects: 639
Study 34597872 — intervention group
Group type: COMPARATOR
Intervention: Anticipated consequence manipulation (control condition).
Number of subjects: 639
Study 35029629 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous casirivimab and imdevimab, 1200 mg (600 mg of each)
Number of subjects: 314
Study 35029629 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 314
Study 32589451 — intervention group
Group type: EXPERIMENTAL
Intervention: NRTIs tenofovir alafenamide (TAF)/FTC
Number of subjects: 77590
Study 32589451 — intervention group
Group type: EXPERIMENTAL
Intervention: NRTIs tenofovir disoproxil fumarate (TDF)/FTC
Number of subjects: 77590
Study 32589451 — intervention group
Group type: EXPERIMENTAL
Intervention: NRTIs abacavir (ABC)/lamivudine (3TC)
Number of subjects: 77590
Study 32589451 — intervention group
Group type: EXPERIMENTAL
Intervention: Other regimens
Number of subjects: 77590
Study 34995536 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF)
Number of subjects: 119
Study 34995536 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study 34995536 — intervention group
Group type: COMPARATOR
Intervention: TDF vs placebo
Number of subjects: 119
Study 34995536 — intervention group
Group type: COMPARATOR
Intervention: TDF and placebo
Number of subjects: 119
Study 34464237 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP titrated to end‐expiratory transpulmonary pressure near 0 cm H2O
Number of subjects: 200
Study 32133931 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive group ($10/day maximum for providing blood samples with reduced or undetectable viral load)
Number of subjects: 102
Study 32133931 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive group
Number of subjects: 102
Study 32133931 — intervention group
Group type: COMPARATOR
Intervention: Usual Care group (no incentives)
Number of subjects: 102
Study 32133931 — intervention group
Group type: COMPARATOR
Intervention: Usual Care group
Number of subjects: 102
Study 35638533 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of rectal diclofenac every 12 hours plus 30 mg of intramuscular pentazocine every 6 hours (group A)
Number of subjects: 200
Study 35638533 — intervention group
Group type: COMPARATOR
Intervention: 60 mg of intramuscular pentazocine every 6 hours (group B)
Number of subjects: 200
Study 34132880 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (3 mg/kg)
Number of subjects: 16
Study 34132880 — intervention group
Group type: COMPARATOR
Intervention: Placebo (cellulose)
Number of subjects: 16
Study 36030815 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise program
Number of subjects: 26
Study 36030815 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight training program
Number of subjects: 26
Study 36030815 — intervention group
Group type: COMPARATOR
Intervention: Cameron's stage four sexual maturation participants
Number of subjects: 26
Study 32761069 — intervention group
Group type: EXPERIMENTAL
Intervention: D‐PRESCRIBE intervention (pharmacist-led education)
Number of subjects: 0
Study 32761069 — intervention group
Group type: EXPERIMENTAL
Intervention: D‐PRESCRIBE intervention
Number of subjects: 0
Study 32761069 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 35903378 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensive intervention group (traditional and mHealth occupational health education)
Number of subjects: 1211
Study 35903378 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensive intervention group (low-intensive group activities and peer education)
Number of subjects: 1211
Study 35903378 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1211
Study 32979724 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet enriched with fatty fish (2 meals/week, ≥150 g cooked filleted fish/meal)
Number of subjects: 64
Study 32979724 — intervention group
Group type: COMPARATOR
Intervention: Usual diet (control group)
Number of subjects: 64
Study 35119198 — intervention group
Group type: EXPERIMENTAL
Intervention: Decontextualisation test involving logical reasoning problems
Number of subjects: 52
Study 35264990 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (120 mg perioperative oral)
Number of subjects: 52
Study 35264990 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 35264990 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 52
Study 32556857 — intervention group
Group type: EXPERIMENTAL
Intervention: CAUTI cases
Number of subjects: 1045
Study 35555638 — intervention group
Group type: COMPARATOR
Intervention: Water (WAT)
Number of subjects: 4
Study 35555638 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatorade (GAT)
Number of subjects: 4
Study 35555638 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk permeate solution (GoodSport, GS)
Number of subjects: 4
Study 32213126 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality Exercise (VRE)
Number of subjects: 80
Study 32213126 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Exercise (TE)
Number of subjects: 80
Study 32213126 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 80
Study 35586982 — intervention group
Group type: EXPERIMENTAL
Intervention: Dehydrated cell and protein concentrate (dCPC)
Number of subjects: 51
Study 35586982 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid (CSI)
Number of subjects: 51
Study 33231919 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic stress (administered via four distinct anthropogenic stressors for 30 minutes daily for 21 days)
Number of subjects: 0
Study 33231919 — intervention group
Group type: COMPARATOR
Intervention: Control (non-stressed birds)
Number of subjects: 0
Study 32956419 — intervention group
Group type: EXPERIMENTAL
Intervention: Early HAART (started within 5 days of ICU admission)
Number of subjects: 115
Study 32956419 — intervention group
Group type: COMPARATOR
Intervention: Late HAART (started after discharge from the ICU)
Number of subjects: 115
Study 35994794 — intervention group
Group type: COMPARATOR
Intervention: Stable weight or gain
Number of subjects: 3504
Study 35994794 — intervention group
Group type: COMPARATOR
Intervention: <5% weight loss
Number of subjects: 3504
Study 35994794 — intervention group
Group type: COMPARATOR
Intervention: ≥5% weight loss
Number of subjects: 3504
Study 34473018 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac surgery (CABG, isolated mitral valve, isolated aortic valve, combined surgical procedures)
Number of subjects: 49
Study 34473018 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative preparation time ≤2 days
Number of subjects: 49
Study 34473018 — intervention group
Group type: EXPERIMENTAL
Intervention: Body surface area (BSA) <1.85 m2
Number of subjects: 49
Study 34473018 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly developing atrial fibrillation (AF)
Number of subjects: 49
Study 34473018 — intervention group
Group type: EXPERIMENTAL
Intervention: History of previous cerebrovascular events
Number of subjects: 49
Study 34473018 — intervention group
Group type: EXPERIMENTAL
Intervention: Total anterior circulation infarction (TACI)
Number of subjects: 49
Study 34473018 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial anterior circulation infarction (PACI)
Number of subjects: 49
Study 34473018 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior circulation infarction (POCI)
Number of subjects: 49
Study 34473018 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortical border zone infarction (CBZI)
Number of subjects: 49
Study 34473018 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined POCI + CBZI
Number of subjects: 49
Study 34473018 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple territorial infarcts (MTI)
Number of subjects: 49
Study 34473018 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacunar circulation infarction (LACI)
Number of subjects: 49
Study 34473018 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Rankin Scale following AIS
Number of subjects: 49
Study 32938410 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Control Training (CCT)
Number of subjects: 88
Study 32938410 — intervention group
Group type: COMPARATOR
Intervention: Active placebo control
Number of subjects: 88
Study 36155369 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine patch (5 mcg every hour)
Number of subjects: 150
Study 36155369 — intervention group
Group type: COMPARATOR
Intervention: Tramadol injections (100 mg every 8 hours)
Number of subjects: 150
Study 33415357 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternate part-time patching
Number of subjects: 76
Study 33415357 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 76
Study 35975404 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibegron 75 mg once daily for 12 weeks
Number of subjects: 222
Study 35975404 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 222
Study 35975404 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibegron 75 mg
Number of subjects: 222
Study 33624862 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple imputation
Number of subjects: 0
Study 33624862 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity analyses
Number of subjects: 0
Study 33624862 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical framework
Number of subjects: 0
Study 33624862 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohort study, multi-centre case control study, randomised clinical trial
Number of subjects: 0
Study 32321085 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-integrated cognitive behavior therapy (MICBT)
Number of subjects: 20
Study 34973410 — intervention group
Group type: EXPERIMENTAL
Intervention: Website-based learning contents for ADR monitoring
Number of subjects: 60
Study 34973410 — intervention group
Group type: COMPARATOR
Intervention: Small notebook for monitoring ADRs
Number of subjects: 60
Study 34011049 — intervention group
Group type: EXPERIMENTAL
Intervention: Warming needle moxibustion treatment for ankylosing spondylitis for 30 days followed by a 6-month follow-up.
Number of subjects: 0
Study 34011049 — intervention group
Group type: COMPARATOR
Intervention: Control group (specific intervention details not provided).
Number of subjects: 0
Study 33211166 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional class I or II
Number of subjects: 563
Study 33211166 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-Minute Walk Distance (6MWD) ≥ 380 m
Number of subjects: 563
Study 33211166 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-Minute Walk Distance (6MWD) ≥ 440 m
Number of subjects: 563
Study 33211166 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac index > 2.5 L/min/m2
Number of subjects: 563
Study 33211166 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional class I or II and 6MWD ≥ 440 m
Number of subjects: 563
Study 35212235 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal esketamine 84 mg
Number of subjects: 27
Study 35212235 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 35212235 — intervention group
Group type: COMPARATOR
Intervention: Placebo baseline SDLP
Number of subjects: 27
Study 34246251 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-opioid prescription
Number of subjects: 0
Study 34246251 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study 33017662 — intervention group
Group type: EXPERIMENTAL
Intervention: Quizartinib
Number of subjects: 367
Study 33017662 — intervention group
Group type: COMPARATOR
Intervention: Salvage chemotherapy
Number of subjects: 367
Study 33017662 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment arms
Number of subjects: 367
Study 35768915 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based intervention (CBI) including nurse training/mentorship, health education by village health workers, adherence support, and multidisciplinary team meetings
Number of subjects: 547
Study 35768915 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care (SOC)
Number of subjects: 547
Study 35768915 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based intervention (CBI)
Number of subjects: 547
Study 33638646 — intervention group
Group type: EXPERIMENTAL
Intervention: 125I seeds
Number of subjects: 0
Study 33638646 — intervention group
Group type: COMPARATOR
Intervention: Hookwire localization
Number of subjects: 0
Study 33638646 — intervention group
Group type: COMPARATOR
Intervention: 125I seeds vs Hookwire localization
Number of subjects: 0
Study 32407242 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ketone ester (KE) intake (60 g carbohydrates/h combined with three boluses of 25, 20, and 20 g (R)-3-hydroxybutyl (R)-3-hydroxybutyrate)
Number of subjects: 12
Study 32407242 — intervention group
Group type: COMPARATOR
Intervention: Control drink (CON)
Number of subjects: 12
Study 36302570 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Number of subjects: 0
Study 36302570 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34690339 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term-focused training on the Tuebingen trainer
Number of subjects: 18
Study 34690339 — intervention group
Group type: COMPARATOR
Intervention: Nontrainee group (control)
Number of subjects: 18
Study 33305513 — intervention group
Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan (target dose 97/103 mg twice daily)
Number of subjects: 0
Study 33305513 — intervention group
Group type: COMPARATOR
Intervention: valsartan (target dose 160 mg twice daily)
Number of subjects: 0
Study 33305513 — intervention group
Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan
Number of subjects: 0
Study 36427015 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip Arthroscopy
Number of subjects: 99
Study 36427015 — intervention group
Group type: COMPARATOR
Intervention: Physical Therapy
Number of subjects: 99
Study 33650839 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐Paced Walking Test (SPWT)
Number of subjects: 180
Study 33650839 — intervention group
Group type: EXPERIMENTAL
Intervention: Swiss Spinal Stenosis Questionnaire (SSS)
Number of subjects: 180
Study 33650839 — intervention group
Group type: EXPERIMENTAL
Intervention: Oswestry Disability Index (ODI)
Number of subjects: 180
Study 34906007 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcultural Nursing Course (TNC)
Number of subjects: 100
Study 34906007 — intervention group
Group type: COMPARATOR
Intervention: Control group (no TNC)
Number of subjects: 100
Study 34148852 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended cervical laminoplasty with unilateral C4-5 foraminotomy
Number of subjects: 20
Study 32779826 — intervention group
Group type: EXPERIMENTAL
Intervention: Over-the-phone supportive care tailored to the needs of oral cancer patients, provided by a health professional
Number of subjects: 25
Study 34339490 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led intervention (Young & Active) facilitated by peer mentors (PMs) during the school year 2016-2017.
Number of subjects: 30
Study 34339490 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led intervention (Young & Active) facilitated by peer mentors (PMs).
Number of subjects: 30
Study 34339490 — intervention group
Group type: COMPARATOR
Intervention: Control group (15 control schools).
Number of subjects: 30
Study 35148541 — intervention group
Group type: EXPERIMENTAL
Intervention: Clipping
Number of subjects: 80
Study 35148541 — intervention group
Group type: COMPARATOR
Intervention: No clipping
Number of subjects: 80
Study 33227441 — intervention group
Group type: EXPERIMENTAL
Intervention: 42.6 Gy in 10 fractions (Fx)
Number of subjects: 32